TY - JOUR
T1 - Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men
AU - Rositch, Anne F.
AU - Hudgens, Michael G.
AU - Backes, Danielle M.
AU - Moses, Stephen
AU - Agot, Kawango
AU - Nyagaya, Edith
AU - Snijders, Peter J.F.
AU - Meijer, Chris J.L.M.
AU - Bailey, Robert C.
AU - Smith, Jennifer S.
N1 - Funding Information:
Potential conflicts of interest. C. J. L. M. M. has received speaker fees from and P. J. F. S. has been an advisory board member of GlaxoSmithK-line (GSK). J. S. S. has received consultancy and research grants from GSK and Merck Corporation. All other authors report no potential conflicts.
Funding Information:
Financial support. This work was supported by the National Cancer Institute, National Institutes of Health (NIH) (grant R01 CA114773-04; Principal Investigator [P.I.]: J. S. Smith) and the University of North Carolina Center for AIDS Research (grant 5 P30 AI050410-13 from the National Institute of Allergy and Infectious Diseases [NIAID], NIH; P.I.: R. Swanstrom). The RCT was supported by the Division of AIDS, NIAID, NIH (grant AI50440, P.I.: R. C. Bailey) and by the Canadian Institutes of Health Research. A. F. Rositch was supported by an NIH predoctoral training grant in infectious disease epidemiology (grant T32 AI070114; P.I.: S. Meshnick) and postdoctoral training grant in cancer epidemiology (grant T32 CA009314; P.I.: E. Platz).
PY - 2012/9/1
Y1 - 2012/9/1
N2 - Background.Little is known about type-specific associations between prevalent human papillomavirus (HPV) infections and risk of acquiring other HPV types in men. Data on natural clustering of HPV types are needed as a prevaccine distribution to which postvaccine data can be compared.Methods.Using data from a randomized controlled trial of male circumcision in Kisumu, Kenya, adjusted mean survival ratios were estimated for acquisition of any-HPV, high-risk (HR) HPV, and individual HR-HPV types among men uninfected as compared to those infected with vaccine-relevant HPV types 16, 18, 31, 45, 6, or 11 at baseline.Results.Among 1097 human immunodeficiency virus-negative, uncircumcised men, 2303 incident HPV infections were detected over 2534 person-years of follow-up. Although acquisition of individual HR-HPV types varied by baseline HPV type, there was no clear evidence of shorter times to acquisition among men without vaccine-relevant HPV-16, -18, -31, -45, -6, or -11 infections at baseline, as compared to men who did have these infections at baseline.Conclusions.These prospective data on combinations of HPV infections over time do not suggest the potential for postvaccination HPV type replacement. Future surveillance studies are needed to definitely determine whether elimination of HPV types by vaccination will alter the HPV type distribution in the population.
AB - Background.Little is known about type-specific associations between prevalent human papillomavirus (HPV) infections and risk of acquiring other HPV types in men. Data on natural clustering of HPV types are needed as a prevaccine distribution to which postvaccine data can be compared.Methods.Using data from a randomized controlled trial of male circumcision in Kisumu, Kenya, adjusted mean survival ratios were estimated for acquisition of any-HPV, high-risk (HR) HPV, and individual HR-HPV types among men uninfected as compared to those infected with vaccine-relevant HPV types 16, 18, 31, 45, 6, or 11 at baseline.Results.Among 1097 human immunodeficiency virus-negative, uncircumcised men, 2303 incident HPV infections were detected over 2534 person-years of follow-up. Although acquisition of individual HR-HPV types varied by baseline HPV type, there was no clear evidence of shorter times to acquisition among men without vaccine-relevant HPV-16, -18, -31, -45, -6, or -11 infections at baseline, as compared to men who did have these infections at baseline.Conclusions.These prospective data on combinations of HPV infections over time do not suggest the potential for postvaccination HPV type replacement. Future surveillance studies are needed to definitely determine whether elimination of HPV types by vaccination will alter the HPV type distribution in the population.
UR - http://www.scopus.com/inward/record.url?scp=84864946551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864946551&partnerID=8YFLogxK
U2 - 10.1093/infdis/jis406
DO - 10.1093/infdis/jis406
M3 - Article
C2 - 22711906
AN - SCOPUS:84864946551
SN - 0022-1899
VL - 206
SP - 669
EP - 677
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 5
ER -